Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meissner, M.
Right arrow Articles by Seliger, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meissner, M.
Right arrow Articles by Seliger, B.
Clinical Cancer Research Vol. 11, 2552-2560, April 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome

Markus Meissner1,3, Torsten E. Reichert2, Martin Kunkel2, William Gooding5, Theresa L. Whiteside6, Soldano Ferrone7 and Barbara Seliger1,4

Authors' Affiliations: Departments of 1 Internal Medicine and 2 Oral and Maxillofacial Surgery, Johannes Gutenberg-University, Mainz; 3 Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt; 4 Institute of Medical Immunology, Martin-Luther University, Halle, Germany; 5 Division of Biostatistics and 6 Departments of Pathology and Otolaryngology, School of Medicine and Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania; and 7 Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Barbara Seliger, Institute of Medical Immunology, Martin-Luther University, Magdeburger Str. 2, 06112 Halle, Germany. Phone: 49-345-557-4054; Fax: 49-345-557-4055; E-mail: Barbara.Seliger{at}medizin.uni-halle.de.

Purpose: Human leukocyte antigen (HLA) class I antigen defects, which are frequently present in head and neck squamous cell carcinoma (HNSCC) cells may provide the tumor with an escape mechanism from immune surveillance. Scanty information is available about mechanisms underlying HLA class I antigen defects in both lesions and cell lines from HNSCC. In this study, we investigate the role of antigen processing machinery (APM) component abnormalities in the generation of deficient HLA class I surface expression of HNSCC cells.

Experimental Design: Using immunohistochemistry, Western blot, and RT-PCR analyses we correlated the expression of the IFN-{gamma} inducible proteasome subunits and of the peptide transporter TAP with that of HLA class I antigens in biopsies and cell lines from primary, recurrent, and metastatic HNSCC. Furthermore, APM component and HLA class I antigen expression in surgically removed lesions were correlated with the course of the disease in order to assess the clinical significance of deficient expression of these molecules.

Results: A high frequency of LMP2, LMP7, and TAP1 down-regulation or loss was found in tumor lesions and cell lines obtained from HNSCC cancer patients. These defects could be corrected by incubating cells with IFN-{gamma}. Furthermore, LMP2, LMP7, TAP1, TAP2, and HLA class I antigen expression rates in primary HNSCC lesions were found to predict overall survival. Lastly, the level of LMP7 expression was significantly associated with disease recurrence at 2 years.

Conclusions: Our results suggest that the analysis of APM component expression in HNSCC lesions can provide useful prognostic information in patients with HNSCC.

Key Words: head and neck cancer • MHC class I • antigen processing • prognostic marker




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
L. Y. Han, M. S. Fletcher, D. L. Urbauer, P. Mueller, C. N. Landen, A. A. Kamat, Y. G. Lin, W. M. Merritt, W. A. Spannuth, M. T. Deavers, et al.
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma
Clin. Cancer Res., June 1, 2008; 14(11): 3372 - 3379.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Raffaghello, P. Nozza, F. Morandi, M. Camoriano, X. Wang, M. L. Garre, A. Cama, G. Basso, S. Ferrone, C. Gambini, et al.
Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma
Cancer Res., June 1, 2007; 67(11): 5471 - 5478.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. L. Ferris, T. L. Whiteside, and S. Ferrone
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer.
Clin. Cancer Res., July 1, 2006; 12(13): 3890 - 3895.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al.
Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity.
Cancer Res., June 15, 2006; 66(12): 6387 - 6394.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Anichini, R. Mortarini, D. Nonaka, A. Molla, C. Vegetti, E. Montaldi, X. Wang, and S. Ferrone
Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients.
Cancer Res., June 15, 2006; 66(12): 6405 - 6411.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Bazzaro, M. K. Lee, A. Zoso, W. L.H. Stirling, A. Santillan, I.-M. Shih, and R. B.S. Roden
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Cancer Res., April 1, 2006; 66(7): 3754 - 3763.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Lopez-Albaitero, J. V. Nayak, T. Ogino, A. Machandia, W. Gooding, A. B. DeLeo, S. Ferrone, and R. L. Ferris
Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL
J. Immunol., March 15, 2006; 176(6): 3402 - 3409.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Heink, B. Fricke, D. Ludwig, P.-M. Kloetzel, and E. Kruger
Tumor Cell Lines Expressing the Proteasome Subunit Isoform LMP7E1 Exhibit Immunoproteasome Deficiency
Cancer Res., January 15, 2006; 66(2): 649 - 652.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.